Comparative effects of enavogliflozin versus dapagliflozin on adipokines in patients with type 2 diabetes mellitus: a pooled analysis of two randomized controlled trials
Enavogliflozin showed a greater reduction in leptin than dapagliflozin, which persisted after adjustment for weight change, and changes in leptin correlated positively with changes in insulin, C-peptide, and HOMA-IR.
Abstract
Although SGLT2 inhibitor–induced amelioration of adipokines is known to confer cardiometabolic benefits, it remains unclear whether individual SGLT2 inhibitors differ in their effects on adipokine regulation. In this study, we compared the effects of enavogliflozin and dapagliflozin on adipokine levels in patients with type 2 diabetes mellitus (T2DM).
This study is a pooled secondary analysis of two randomized, active-controlled, phase III trials comparing enavogliflozin 0.3 mg (
n
= 214) and dapagliflozin 10 mg (
n
= 213) in patients with T2DM. Serum adipokines (adiponectin and leptin) were measured at baseline and week 24. Analyses were adjusted for baseline values and weight change to determine whether between-treatment differences in adipokine changes persisted after accounting for body weight change, and associations between adipokine changes and key metabolic parameters were assessed.
After 24 weeks, both SGLT2 inhibitors significantly reduced HbA1c with no between-group difference (− 0.92% vs. −0.87%). Adiponectin increased in both groups (1.61 vs. 1.26 mg/L) without a significant difference (rank-based ANCOVA
P
= 0.3520). Leptin decreased in both groups, with a greater reduction observed with enavogliflozin than with dapagliflozin (− 2.08 vs. −1.09 µg/L, rank-based ANCOVA
P
= 0.0113), and this difference persisted after adjustment for weight change and other covariates. In the minimal weight loss group (< 3%), leptin decreased with enavogliflozin (− 0.90 µg/L) but increased with dapagliflozin (1.71 µg/L;
P
= 0.020), whereas no between-group difference was seen in the effective weight loss group (≥ 3%). Changes in leptin correlated positively with changes in insulin, C-peptide, and HOMA-IR.
Enavogliflozin showed a greater reduction in leptin than dapagliflozin, which persisted after adjustment for weight change.
Dipeptidyl peptidase-4 inhibitors and thiazolidinediones are commonly used as add-ons in type 2 diabetes mellitus (T2DM) treatment, but comparative data are limited. This study emulated a target trial to compare sitagliptin and pioglitazone in patients on metformin and sulfonylurea, focusing on changes in glycemic cont...
Tae Hyeon Kim, Yerin Hwang, Se-Lin Woo et al.· Medicine· 0 citations
The aim of the current study was to compare clinical effectiveness and safety profile of Empagliflozin and Dapagliflozin in patients with type 2 diabetes mellitus.This was a prospective comparative study involving a total of n = 120 patients with type 2 diabetes mellitus, who were split into two equal groups; Group A (...
S. S., Maheshwari P, K. K. et al.· World Journal of Current Med...· 0 citations
In postmenopausal women with T2DM, BMD remained stable with evogliptin, whereas dapagliflozin was associated with a small reduction in femoral neck BMD, although this finding was weakened after adjustment.
Hyun Jin Ryu, So Young Park, H. Kim et al.· Diabetes, Metabolic Syndrome...· 0 citations
It is suggested that dapagliflozin exposure is associated with triglyceride-lowering effects, demonstrating an exposure-response relationship supported by pharmacometric analysis of long-term real-world data and a dyslipidemia model.
Ryosuke Terada, Shinji Kobuchi, Ayaka Anada et al.· Xenobiotica; the fate of for...· 0 citations
Background: Type 2 diabetes mellitus (T2DM) is a chronic global health burden associated with cardiovascular (CV) and renal complications. This study aimed to evaluate real-world efficacy, cardiometabolic outcomes, and long-term outcomes of the empagliflozin + linagliptin add-on therapy to metformin in T2DM patients.
M...
Nandkishor Shingne, Vrunda Patel, Swati Tiwari et al.· World Journal of Advanced Re...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.